Lv3
370 积分 2024-09-21 加入
Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials
12天前
已完结
Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study)
12天前
已完结
Biomarkers of Histological Response in Lanifibranor-treated Patients With Metabolic Dysfunction-associated Steatohepatitis
12天前
已完结
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
12天前
已完结
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
12天前
已完结
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
1个月前
已完结
Association Between GLP‐1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta‐Analysis
1个月前
已完结
Association Between GLP‐1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta‐Analysis
1个月前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
1个月前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
